Skip to main content

6 Result(s)

within J. P. Droz Remove this filter Medicine & Public Health Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors

    Objective: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with advanced or metastatic urothelial tract tumors refractory to one prior chemotherapy...

    M.J.A. de Jonge, J.P. Droz, L. Paz-Ares, A.T. van Oosterom… in Investigational New Drugs (2004)

  2. No Access

    Article

    Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

     Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor m...

    C. Maulard, J. P. Droz, D. Jessueld, M. Housset… in Cancer Chemotherapy and Pharmacology (1995)

  3. No Access

    Article

    Phase I–II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer

    Lanreotide (BIM 32014), a somatulin analogue, was found to be as effective as castration in a rat prostate tumor model. Therapeutic benefit was also demonstrated in the hormone-resistant phase of this tumor mo...

    C. Maulard, P. Richaud, J. P. Droz, D. Jessueld… in Cancer Chemotherapy and Pharmacology (1995)

  4. No Access

    Chapter and Conference Paper

    No advantage for the use of an early high-dose chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors

    The results of the treatment of non-seminomatous germ cell tumors (NSGCT) have been dramatically improved by Cisplatin-based chemotherapy regimens and selective indication of surgery. Approximately 80 % of all...

    H. Curé, J. P. Droz, J. L. Pico, P. Biron, P. Kerbrat… in Cancer Treatment An Update (1994)

  5. No Access

    Article

    Phase II trial of pirarubicin in the treatment of advanced bladder cancer

    Doxorubicin is one of the standard drugs in the chemotherapy of advanced urothelial tumors. Pirarubicin, a new anthracycline, turned out to be equally active and less toxic than its parent compound in preclini...

    M. Mahjoubi, J. Kattan, M. Ghosn, J. -P. Droz, I. Philippot… in Investigational New Drugs (1992)

  6. No Access

    Chapter and Conference Paper

    High-dose chemotherapy with hematologic rescue for high-risk non-seminomatous germ cell tumors

    Despite progress in the treatment of disseminated non-seminomatous germ cell tumors (NSGCT), 20–30%of patients do not achieve CR or relapse [1]. We evaluated high-dose chemotherapy (HDC) followed by autologous...

    J. L. Pico, J. P. Droz, E. Zambon… in Proceedings of the 3rd International Congr… (1991)